Thermo, It does appear the trial data is being well received although limited to mostly the same physicians who've always been in the mix. When there's a negative article...And there will very likely be a negative article at some point poking holes...Who's going to address it, LG on the BigBiz Show? Are you at all shocked they went that route knowing the 2018 interim actually did have merit?
I still don't see the telltale signs for commercialization. Almost feels like they're gearing up for compassionate use assisted by EU government funding. And, if that's the case, Advent should do well. Are you still interested in bringing Advent back home?
According to NovaCure they're treating thirty percent of patients so that seems pretty significant.
----------
Horse, Interesting the tumor load thesis. I wish the journal had explained that better. Actually there's a lot I wish it explained better.
Market Data 
Markets 
AI
